stockrowZymeworks Inc.
ZYME Healthcare Biotechnology
Zymeworks Inc.’s revenue for fiscal 2025 (year ended December 2025) was $106.0 million, up 38.9% from fiscal 2024.
- Revenue
- −90.6%
- EPS
- −2,166.7%
- Free cash flow
- −385.5%
Quarter to June 2026, against a year earlier
Follow ZYME
Alert me
Zymeworks Inc. (ZYME) Net margin
Zymeworks Inc.'s net margin over the twelve months to 30 June 2026 was −404.0%, down 327.4 percentage points from fiscal 2025 (−76.6%). Over the past ten years it has ranged from −794.0% (fiscal 2021) to 30.1% (fiscal 2022); the current reading is higher than 73% of that period. That is below the Biotechnology industry median of 0.00% and below the Healthcare sector median of 0.00%.
Net margin, annual
Embed this chart
Annual newest first
| Period | Net margin | Change (points) |
|---|---|---|
| FY2025 | −76.6% | 84.24 |
| FY2024 | −160.8% | (4.67) |
| FY2023 | −156.1% | (186.27) |
| FY2022 | 30.1% | 824.15 |
| FY2021 | −794.0% | (330.47) |
| FY2020 | −463.5% | 28.73 |
| FY2019 | −492.3% | (423.32) |
| FY2018 | −69.0% | (47.84) |
| FY2017 | −21.1% | 285.99 |
| FY2016 | −307.1% | (108.65) |
Quarterly newest first
| Period | Net margin | Change (points) |
|---|---|---|
| Jun 2026 | −980.8% | 853.16 |
| Mar 2026 | −1,834.0% | (195.44) |
| Dec 2025 | −1,638.5% | (1,567.54) |
| Sep 2025 | −71.0% | (75.75) |
| 38 more quarters | Free account |
Against its own ten years
Net margin against peers
| Company | Net margin |
|---|---|
| AUPH Aurinia Pharmaceuticals Inc compare | 97.7% |
| VCEL Vericel Corporation compare | 10.3% |
| IMNM Immunome, Inc. compare | 0.00% |
| VERA Vera Therapeutics, Inc. compare | 0.00% |
| BHVN Biohaven Ltd. compare | 0.00% |
| COAG Hemab Therapeutics Holdings, Inc. compare | 0.00% |
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | −6.81% |
| SEPN Septerna, Inc. compare | −24.5% |
| ZYME Zymeworks Inc. | −404.0% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 1.06% |
What Net margin is
Net Profit Margin tells an investor how much of each unit of revenue ends up as profit for shareholders after all costs, interest and taxes.
Net Income Allotted to Shareholders ÷ Revenue
More on ZYME
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement